Disease Area
Target ID
Chemistry & Lead Optimisation
Phase 1
Phase 2
(multiple indications & targets in therapy areas such as Oncology, Immunology, CNS, GI, Metabolic Disorders and Others)

Case Studies


Atopic Dermatitis

Atopic Dermatitis is the most prevalent type of eczema. The drug we developed to treat the inflammation and itch associated with the disease is currently being tested in human clinical trials.

View Case Study


Ulcerative Colitis (UC)

UC is a chronic disease with no cure. Our work focuses on discovering safer and more effective small-molecule treatments, and we have identified and validated a novel AI-generated target with no previous link to UC.

View Case Study


Glioblastoma Multiforme (GBM)

GBM is a complex, aggressive and lethal brain tumour. Our work focuses on mechanisms that may contribute to the progression and relapse of the disease, and we advanced one of the most promising candidates through to lead optimisation.

View Case Study


Amyotrophic Lateral Sclerosis

ALS is a progressive and ultimately fatal neurodegenerative disease. Our two programmes aim to identify targets to treat ALS, and we have progressed two targets to candidate seeking and lead optimization.

View Case Study

Drug development licensing partnerships

Our pipeline demonstrates the utility of the Benevolent Platform™, and we are actively exploring strategic licensing partnerships and late-stage development and commercialisation partnerships to deliver our medicines to patients in need.


We innovate at every stage of the drug discovery process

By fusing artificial and human intelligence, we empower scientists to uncover new relationships between diseases and symptoms, drugs and their effects and the subgroups of patients who will respond to treatment.